Takeda, Seattle Genetics Of U.S. Report Positive Trial Of Hodgkin's Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical and U.S. partner Seattle Genetics reported early success with a drug they co-developed to treat Hodgkin's lymphoma